文献速递免疫规划传染病防控与疫情报告

二价mRNA加强针预防奥密克戎BA.5及XBB/XBB.1.5相关亚系所致有症状SARS-CoV-2感染的早期疫苗有效性估计——增加社区检测机会项目,美国,2022年12月至2023年1月

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-02-03

利用美国ICATT药房检测项目数据,分析2022年12月1日至2023年1月13日期间免疫功能正常成人中二价mRNA疫苗对BA.5相关及XBB/XBB.1.5相关亚系所致有症状感染的疫苗有效性。在29,175份有SGTF或SGTP结果的核酸检测中,18-49岁人群接种二价加强针后2-3个月相对未接种二价加强针的疫苗有效性为:针对有症状BA.5感染52%,针对有症状XBB/XBB.1.5感染48%。二价疫苗似乎为既往接种2-4剂单价疫苗者提供额外保护。

要点

  • 18-49岁成人接种二价加强针后2-3个月,针对有症状BA.5感染的相对VE为52%。
  • 同人群中针对有症状XBB/XBB.1.5感染的相对VE为48%。
  • 二价疫苗似乎为既往接种2、3或4剂单价疫苗者提供额外保护。

核心结论

  • 二价疫苗似乎为既往接种2、3或4剂单价COVID-19疫苗者提供针对有症状BA.5相关亚系和XBB/XBB.1.5相关亚系感染的额外保护。
  • 随着新SARS-CoV-2变异株出现,继续开展疫苗有效性监测很重要。
  • 所有人员应及时接种推荐的COVID-19疫苗,符合条件时接种二价加强针。

研究设计与样本

  • 分析美国Increasing Community Access to Testing(ICATT)国家药房SARS-CoV-2检测项目数据,估计2022年12月1日至2023年1月13日期间二价mRNA COVID-19疫苗对免疫功能正常成人有症状感染的疫苗有效性。
  • 利用实时逆转录聚合酶链反应(RT-PCR)中刺突基因(S基因)扩增减少或失败(SGTF)作为可能BA.5相关亚系感染的替代指标,S基因靶标存在(SGTP)作为可能XBB/XBB.1.5相关亚系感染的替代指标。
  • 分析对象为既往接种2-4剂单价COVID-19疫苗且有SGTF或SGTP结果的成人,共29,175份核酸检测。

主要发现

  • 在29,175份有SGTF或SGTP结果的核酸检测中,18-49岁人群接种二价加强针后2-3个月相对未接种二价加强针的疫苗有效性为:针对有症状BA.5感染52%,针对有症状XBB/XBB.1.5感染48%。
  • XBB与XBB.1.5在2022年12月31日前占东北部测序谱系的>50%,截至2023年1月21日占全国测序谱系的52%。

临床怎么用

  • 所有人员应及时接种推荐的COVID-19疫苗,符合条件时接种二价加强针。
  • 随着新SARS-CoV-2变异株出现,继续开展疫苗有效性监测很重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The SARS-CoV-2 Omicron sublineage XBB was first detected in the United States in August 2022.* XBB together with a sublineage, XBB.1.5, accounted for >50% of sequenced lineages in the Northeast by December 31, 2022, and 52% of sequenced lineages nationwide as of January 21, 2023. COVID-19 vaccine effectiveness (VE) can vary by SARS-CoV-2 variant; reduced VE has been observed against some variants, although this is dependent on the health outcome of interest. The goal of the U.S. COVID-19 vaccination program is to prevent severe disease, including hospitalization and death (1); however, VE against symptomatic infection can provide useful insight into vaccine protection against emerging variants in advance of VE estimates against more severe disease. Data from the Increasing Community Access to Testing (ICATT) national pharmacy program for SARS-CoV-2 testing were analyzed to estimate VE of updated (bivalent) mRNA COVID-19 vaccines against symptomatic infection caused by BA.5-related and XBB/XBB.1.5-related sublineages among immunocompetent adults during December 1, 2022–January 13, 2023. Reduction or failure of spike gene (S-gene) amplification (SGTF) in real-time reverse transcription–polymerase chain reaction (RT-PCR) was used as a proxy indicator of infection with likely BA.5-related sublineages and S-gene target presence (SGTP) of infection with likely XBB/XBB.1.5-related sublineages (2). Among 29,175 nucleic acid amplification tests (NAATs) with SGTF or SGTP results available from adults who had previously received 2–4 monovalent COVID-19 vaccine doses, the relative VE of a bivalent booster dose given 2–3 months earlier compared with no bivalent booster in persons aged 18–49 years was 52% against symptomatic BA.5 infection and 48% against symptomatic XBB/XBB.1.5 infection. As new SARS-CoV-2 variants emerge, continued vaccine effectiveness monitoring is important. Bivalent vaccines appear to provide additional protection against symptomatic BA.5-related sublineage and XBB/XBB.1.5-related sublineage infections in persons who had previously received 2, 3, or 4 monovalent vaccine doses. All persons should stay up to date with recommended COVID-19 vaccines, including receiving a bivalent booster dose when they are eligible.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Link-Gelles R, Ciesla AA, Roper LE, et al. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36730051. doi:10.15585/mmwr.mm7205e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。